AdultPediatricDosage Forms & Strengths tablets 1mg 2mg Tourette Disorder Initial 1-2 mg PO qDay ; increase every other day; not to exceed 10 mg/day Maintenance: <0.2 mg/kg/day or 10 mg/day, choose lowest dose Dosage Forms & Strengths tablets 1mg 2mg Tourette Disorder < 2 years Safety & efficacy not established 2-12 years Initial: 0.05 mg/kg/day PO qHS Can be increased q3Days to 0.2 mg/kg/day PO qHS Maintenance dose: 2-4 mg/day; not to exceed 10 mg/day >12 years Initial 1-2 mg PO qDay ; increase every other day; not to exceed 10 mg/day Maintenance: <0.2 mg/kg/day or 10 mg/day, choose lowest dose Interaction CheckerEnter a drug name and pimozideNo Results No Interactions Found Interactions FoundContraindicatedSerious - Use AlternativeSignificant - Monitor CloselyMinorAll Interactions Sort By: SeverityName Contraindicated (95)amiodaroneamiodarone and pimozide both increase QTc interval. Contraindicated.amisulprideamisulpride and pimozide both increase QTc interval. Contraindicated.amisulpride, pimozide. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.amitriptylineamitriptyline and pimozide both increase QTc interval. Contraindicated.amoxapineamoxapine and pimozide both increase QTc interval. Contraindicated.aprepitantaprepitant increases levels of pimozide by decreasing metabolism. Contraindicated. Risk of QT interval prolongation.arsenic trioxidearsenic trioxide and pimozide both increase QTc interval. Contraindicated.artemether/lumefantrineartemether/lumefantrine and pimozide both increase QTc interval. Contraindicated.atazanaviratazanavir will increase the level or effect of pimozide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Risk of QT interval prolongation.azithromycinazithromycin increases toxicity of pimozide by decreasing metabolism. Contraindicated. Risk of prolonged QTc interval.bupropionbupropion will increase the level or effect of pimozide by affecting hepatic enzyme CYP2D6 metabolism. Contraindicated. Both bupropion and hydroxybupropion (major metabolite) are considered strong CYP2D6 inhibitors; additionally, bupropion and pimozide lower seizure thresholdchlorpromazinechlorpromazine and pimozide both increase QTc interval. Contraindicated.cimetidinecimetidine increases levels of pimozide by decreasing metabolism. Contraindicated. Risk of QT interval prolongation.citalopramcitalopram and pimozide both increase QTc interval. Contraindicated.clarithromycinclarithromycin and pimozide both increase QTc interval. Contraindicated.clarithromycin increases levels of pimozide by decreasing metabolism. Contraindicated. Risk of QT interval prolongation.clomipramineclomipramine and pimozide both increase QTc interval. Contraindicated.cobicistatcobicistat will increase the level or effect of pimozide by affecting hepatic enzyme CYP2D6 metabolism. Contraindicated. Potential for increased systemic exposure of pimozide resulting in increased risk for QT prolongationcobicistat will increase the level or effect of pimozide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Potential for increased systemic exposure of pimozide resulting in increased risk for QT prolongation.conivaptanconivaptan increases levels of pimozide by decreasing metabolism. Contraindicated. Risk of QT interval prolongation.crizotinibcrizotinib and pimozide both increase QTc interval. Contraindicated. Pimozide is contraindicated with drugs that may prolong the QT interval. Coadministration of crizotinib with CYP3A substrates with narrow therapeutic indices should be avoided.cyclosporinecyclosporine will increase the level or effect of pimozide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.darunavirdarunavir will increase the level or effect of pimozide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration with phenytoin may result in loss of therapeutic effect and development of resistance to darunavir.dasatinibdasatinib increases levels of pimozide by decreasing metabolism. Contraindicated. Risk of QT interval prolongation.desipraminedesipramine and pimozide both increase QTc interval. Contraindicated.diltiazemdiltiazem will increase the level or effect of pimozide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration with potent CYP3A4 inhibitors may significantly increase the plasma concentrations of pimozide and may potentiate the risk of ventricular arrhythmias (eg, ventricular tachycardia, torsade de pointes, cardiac arrest, sudden death).disopyramidedisopyramide and pimozide both increase QTc interval. Contraindicated.dofetilidedofetilide and pimozide both increase QTc interval. Contraindicated.doxepindoxepin and pimozide both increase QTc interval. Contraindicated.dronedaronedronedarone and pimozide both increase QTc interval. Contraindicated.dronedarone increases levels of pimozide by decreasing metabolism. Contraindicated. Risk of QT interval prolongation.droperidoldroperidol and pimozide both increase QTc interval. Contraindicated.elvitegravir/cobicistat/emtricitabine/tenofovir DFelvitegravir/cobicistat/emtricitabine/tenofovir DF increases levels of pimozide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Cobicistat is a CYP3A4 inhibitor; contraindicated with CYP3A4 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events.epinephrineepinephrine and pimozide both increase QTc interval. Contraindicated.epinephrine racemicepinephrine racemic and pimozide both increase QTc interval. Contraindicated.erythromycin baseerythromycin base and pimozide both increase QTc interval. Contraindicated.erythromycin base increases levels of pimozide by decreasing metabolism. Contraindicated. Risk of QT interval prolongation.erythromycin ethylsuccinateerythromycin ethylsuccinate and pimozide both increase QTc interval. Contraindicated.erythromycin ethylsuccinate increases levels of pimozide by decreasing metabolism. Contraindicated. Risk of QT interval prolongation.erythromycin lactobionateerythromycin lactobionate and pimozide both increase QTc interval. Contraindicated.erythromycin lactobionate increases levels of pimozide by decreasing metabolism. Contraindicated. Risk of QT interval prolongation.erythromycin stearateerythromycin stearate and pimozide both increase QTc interval. Contraindicated.erythromycin stearate increases levels of pimozide by decreasing metabolism. Contraindicated. Risk of QT interval prolongation.escitalopramescitalopram and pimozide both increase QTc interval. Contraindicated.fluconazolefluconazole and pimozide both increase QTc interval. Contraindicated.fluconazole increases levels of pimozide by decreasing metabolism. Contraindicated. Risk of QT interval prolongation.fluoxetinefluoxetine and pimozide both increase QTc interval. Contraindicated.fluoxetine increases levels of pimozide by decreasing metabolism. Contraindicated. Risk of QT interval prolongation.fluphenazinefluphenazine and pimozide both increase QTc interval. Contraindicated.fosamprenavirfosamprenavir increases levels of pimozide by decreasing metabolism. Contraindicated. Risk of QT interval prolongation.fosaprepitantfosaprepitant increases levels of pimozide by decreasing metabolism. Contraindicated. Risk of QT interval prolongation.goserelingoserelin increases toxicity of pimozide by QTc interval. Contraindicated. Increases risk of torsades de pointes.haloperidolhaloperidol and pimozide both increase QTc interval. Contraindicated.ibutilideibutilide and pimozide both increase QTc interval. Contraindicated.imipramineimipramine and pimozide both increase QTc interval. Contraindicated.indapamideindapamide and pimozide both increase QTc interval. Contraindicated.itraconazoleitraconazole will increase the level or effect of pimozide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Both drugs will increase QT interval. Coadministration of pimozide and itraconazole is contraindicated during and 2 weeks after itraconazole treatment.ketoconazoleketoconazole and pimozide both increase QTc interval. Contraindicated.ketoconazole increases levels of pimozide by decreasing metabolism. Contraindicated. Risk of QT interval prolongation.lapatiniblapatinib increases levels of pimozide by decreasing metabolism. Contraindicated. Risk of QT interval prolongation.lefamulinlefamulin will increase the level or effect of pimozide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Lefamulin is contraindicated with CYP3A substrates know to prolong the QT interval.letermovirletermovir increases levels of pimozide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration of letermovir and pimozide is contraindicated due to risk of QT prolongations and torsades de pointes.leuprolideleuprolide increases toxicity of pimozide by QTc interval. Contraindicated. Increases risk of torsades de pointes.levoketoconazolelevoketoconazole and pimozide both increase QTc interval. Contraindicated.levoketoconazole increases levels of pimozide by decreasing metabolism. Contraindicated. Risk of QT interval prolongation.lofepraminelofepramine and pimozide both increase QTc interval. Contraindicated.lumefantrinelumefantrine and pimozide both increase QTc interval. Contraindicated.maprotilinemaprotiline and pimozide both increase QTc interval. Contraindicated.marijuanamarijuana increases levels of pimozide by decreasing metabolism. Contraindicated. Risk of QT interval prolongation.miconazole vaginalmiconazole vaginal increases levels of pimozide by decreasing metabolism. Contraindicated. Risk of QT interval prolongation.mifepristonemifepristone increases levels of pimozide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Contraindicated with CYP3A substrates that have a narrow therapeutic index; combination may prolong QT interval .moxifloxacinmoxifloxacin and pimozide both increase QTc interval. Contraindicated.nefazodonenefazodone increases levels of pimozide by decreasing metabolism. Contraindicated. Risk of QT interval prolongation.nelfinavirnelfinavir increases levels of pimozide by decreasing metabolism. Contraindicated. Potential for serious and/or life-threatening reactions (eg, cardiac arrhythmias).nilotinibnilotinib and pimozide both increase QTc interval. Contraindicated.nilotinib increases levels of pimozide by decreasing metabolism. Contraindicated. Risk of QT interval prolongation.nirmatrelvirnirmatrelvir will increase the level or effect of pimozide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Nirmatrelvir/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions.nirmatrelvir/ritonavirnirmatrelvir/ritonavir will increase the level or effect of pimozide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Nirmatrelvir/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions.nortriptylinenortriptyline and pimozide both increase QTc interval. Contraindicated.octreotideoctreotide and pimozide both increase QTc interval. Contraindicated.octreotide (Antidote)octreotide (Antidote) and pimozide both increase QTc interval. Contraindicated.ombitasvir/paritaprevir/ritonavir & dasabuvir (DSC)ombitasvir/paritaprevir/ritonavir & dasabuvir (DSC) will increase the level or effect of pimozide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Potential for cardiac arrhythmiasoxaliplatinoxaliplatin will increase the level or effect of pimozide by Other (see comment). Contraindicated. Monitor for ECG changes if therapy is initiated in patients with drugs known to prolong QT interval.paroxetineparoxetine increases levels of pimozide by affecting hepatic enzyme CYP2D6 metabolism. Contraindicated. Contraindicated. Coadministration increases pimozide AUC and Cmax and may result in prolonged QT interval.pasireotidepimozide and pasireotide both increase QTc interval. Contraindicated.pentamidinepentamidine and pimozide both increase QTc interval. Contraindicated.perphenazineperphenazine and pimozide both increase QTc interval. Contraindicated.procainamidepimozide and procainamide both increase QTc interval. Contraindicated.prochlorperazineprochlorperazine and pimozide both increase QTc interval. Contraindicated.promazinepromazine and pimozide both increase QTc interval. Contraindicated.promethazinepromethazine and pimozide both increase QTc interval. Contraindicated.protriptylineprotriptyline and pimozide both increase QTc interval. Contraindicated.quinidinequinidine and pimozide both increase QTc interval. Contraindicated.quininepimozide and quinine both increase QTc interval. Contraindicated.ritonavirritonavir increases levels of pimozide by decreasing metabolism. Contraindicated. Risk of QT interval prolongation.rolapitantrolapitant will increase the level or effect of pimozide by affecting hepatic enzyme CYP2D6 metabolism. Contraindicated. Rolapitant moderately inhibits CYP2D6. Coadministration with pimozide, a CYP2D6 substrate, causes a significant increase in pimozide plasma concentration that may result in QT prolongation and torsades de pointes.sertralinesertraline increases levels of pimozide by decreasing metabolism. Contraindicated. Risk of prolonged QTc interval.sorafenibsorafenib and pimozide both increase QTc interval. Contraindicated.sotalolpimozide and sotalol both increase QTc interval. Contraindicated.thioridazinethioridazine and pimozide both increase QTc interval. Contraindicated.tipranavirtipranavir increases levels of pimozide by decreasing metabolism. Contraindicated. Risk of QT interval prolongation.toremifenepimozide and toremifene both increase QTc interval. Contraindicated. Concurrent use of pimozide with other agents that prolong QTc interval is contraindicated.trazodonetrazodone and pimozide both increase QTc interval. Contraindicated.trifluoperazinetrifluoperazine and pimozide both increase QTc interval. Contraindicated.trimipraminetrimipramine and pimozide both increase QTc interval. Contraindicated.verapamilverapamil increases levels of pimozide by decreasing metabolism. Contraindicated. Risk of QT interval prolongation.voriconazolevoriconazole will increase the level or effect of pimozide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.voriconazole increases levels of pimozide by decreasing metabolism. Contraindicated. Risk of QT interval prolongation.ziprasidonepimozide and ziprasidone both increase QTc interval. Contraindicated.Serious - Use Alternative (151)abametapirabametapir will increase the level or effect of pimozide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. For 2 weeks after abametapir application, avoid taking drugs that are CYP3A4 substrates. If not feasible, avoid use of abametapir.abametapir will increase the level or effect of pimozide by affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug. For 2 weeks after abametapir application, avoid taking drugs that are CYP1A2 substrates. If not feasible, avoid use of abametapir.adagrasibadagrasib will increase the level or effect of pimozide by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of adagrasib, a CYP2D6 inhibitor, with sensitive CYP2D6 substrates unless otherwise recommended in the prescribing information for these substrates.adagrasib, pimozide. Either increases effects of the other by QTc interval. Avoid or Use Alternate Drug. Each drug prolongs the QTc interval, which may increased the risk of Torsade de pointes, other serious arryhthmias, and sudden death. If coadministration unavoidable, more frequent monitoring is recommended for such patients.albuterolalbuterol and pimozide both increase QTc interval. Contraindicated.alfuzosinalfuzosin and pimozide both increase QTc interval. Contraindicated.anagrelideanagrelide and pimozide both increase QTc interval. Contraindicated.apalutamideapalutamide will decrease the level or effect of pimozide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration of apalutamide, a strong CYP3A4 inducer, with drugs that are CYP3A4 substrates can result in lower exposure to these medications. Avoid or substitute another drug for these medications when possible. Evaluate for loss of therapeutic effect if medication must be coadministered. Adjust dose according to prescribing information if needed.apomorphinepimozide decreases effects of apomorphine by pharmacodynamic antagonism. Avoid or Use Alternate Drug.apomorphine and pimozide both increase QTc interval. Contraindicated.aprepitantaprepitant will increase the level or effect of pimozide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Risk of QT interval prolongation.arformoterolarformoterol and pimozide both increase QTc interval. Contraindicated.aripiprazolearipiprazole and pimozide both increase QTc interval. Contraindicated.artemetherartemether and pimozide both increase QTc interval. Contraindicated.asenapineasenapine and pimozide both increase QTc interval. Contraindicated.asenapine transdermalasenapine transdermal and pimozide both increase QTc interval. Contraindicated.atomoxetineatomoxetine and pimozide both increase QTc interval. Contraindicated.benzhydrocodone/acetaminophenbenzhydrocodone/acetaminophen, pimozide. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.bremelanotidebremelanotide will decrease the level or effect of pimozide by Other (see comment). Avoid or Use Alternate Drug. Bremelanotide may slow gastric emptying and potentially reduces the rate and extent of absorption of concomitantly administered oral medications. Avoid use when taking any oral drug that is dependent on threshold concentrations for efficacy. Interactions listed are representative examples and do not include all possible clinical examples.brigatinibbrigatinib will